GlassScriptPhysician profile
George Cholankeril
NPI 1154760155
$33,504.24
in general payments reported to CMS, 2019-2025
11 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.65 · 2022: $230 · 2023: $384 · 2024: $3,418 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $2,713 · Travel and Lodging: $2,277 · Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,042.38 |
| Consulting Fee | $2,712.50 |
| Travel and Lodging | $2,277.16 |
| Food and Beverage | $2,172.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32,168.81 | 2021-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.87 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $223.01 | 2024-2025 | |
| Cook Medical LLC | $204.00 | 2024 | Echotip Insight |
| Madrigal Pharmaceuticals | $187.11 | 2024-2025 | Resmetirom, Rezdiffra |
| Abbvie INC. | $149.79 | 2021-2023 | Mavyret |
| Mallinckrodt Hospital Products INC. | $119.74 | 2023 | Terlivaz |
| Mirum Pharmaceuticals, INC. | $80.36 | 2025 | Livmarli |
| Orphalan INC | $48.09 | 2023-2025 | Cuvrior |
| Takeda Pharmaceuticals U.S.A., INC. | $46.39 | 2024 | Eohilia, Entyvio |
| Alcresta Therapeutics, INC. | $21.07 | 2023 | Relizorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Cholankeril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.